HCWB

HCWB

HCW Biologics Inc

Net โ€”top 1%Rev โ€”top 1%5Y
Hold

HCW Biologics Inc. develops immunotherapies targeting chronic inflammation, cancer, and autoimmune diseases. Its lead products include HCW9218 for solid tumors and HCW9302 for autoimmune conditions, alongside various novel biologics for advanced treatments.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$3today

Score Overview

1 Year
Score
Net Growth73.49%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth-97.89%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growthโ€”
Net Trendโ€”
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trendโ€”
Revenue Consistencyโ€”
All Time
Score
Net Growth38.12%
Net Trend25%
Net Income Consistency
Rev Growth-98.68%
Rev Trend25%
Revenue Consistency

See the full market ranking โ†’

HCW Biologics Inc fundamental performance

Across HCW Biologics Inc's full reported history, from 2021 to 2025, revenue declined from $ 4M to $ 54.23K and net income went from -$ 12M to -$ 7M. Revenue increased in 25% of the years measured; net income in 25%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 3.15โ€”
1 Year2025-08-12
$ 26.88-88.30%
5 Years2021-08-12
$ 1.21K-99.74%
All Time2021-07-20
$ 1.51K-99.79%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025$ 54.23K-$ 7M$ 1M
2024$ 2M-$ 30M$ 4M
2023$ 2M-$ 24M$ 3M
2022$ 6M-$ 14M$ 32M
IPO2021$ 4M-$ 12M$ 36M

Explore beyond HCWB

You're looking at HCW Biologics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies